ASH 2022 | Managing transfusion dependence in MDS: lenalidomide, ESAs & defining a threshold for transfusion
Moshe Mittelman, MD, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv University, Israel, outlines strategies to manage transfusion dependence in patients with myelodysplastic syndromes (MDS), commenting on the use of lenalidomide and erythropoietin-stimulating agents (ESAs) to delay the need for transfusion and with respect to ESAs, to prolong overall survival (OS). Prof. Mittelman also discusses the need to define an optimal hemoglobin threshold for transfusion. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
